Meeting
2018 Gastrointestinal Cancers Symposium
Pancreatic exocrine insufficiency (PI) secondary to chronic use of long-acting (LA) somatostatin analogues (SA) in patients (pts) with gastroenteropancreatic neuroendocrine tumors (GEP-NETs).
Authors
Wasif M. Saif
Tufts University School of Medicine, Boston, MA
Wasif M. Saif , Melissa H Smith , Rachna Patel , Valerie Relias
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Track
Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Sub Track
Multidisciplinary Treatment
Citation
J Clin Oncol 36, 2018 (suppl 4S; abstr 454)
DOI
10.1200/JCO.2018.36.4_suppl.454
Abstract #
454
Poster Bd #
M1
Abstract Disclosures
Similar Posters
Poster
2021 Gastrointestinal Cancers Symposium
Cost of treatment change among patients with neuroendocrine tumors (NET) treated originally with somatostatin analogs.
First Author: Bernard Tawfik
Poster
2019 ASCO Annual Meeting
Analysis of patient diaries in the NETTER-1 Study of 177Lu-DOTATATE versus high-dose octreotide in progressive midgut neuroendocrine tumors.
First Author: Jonathan R. Strosberg
Poster
2018 Gastrointestinal Cancers Symposium
Living with neuroendocrine tumors: Assessing quality of life (QoL) through a mobile application.
First Author: Jared Adams
Poster
2018 Gastrointestinal Cancers Symposium
Lanreotide for the prolonged control of carcinoid syndrome (CS) in somatostatin analog (SSA)-naïve or experienced patients.
First Author: Edward M. Wolin